Sprycel Shows Promising Efficacy Data in First-Line Metastatic ER+/HER2- Disease
12 Dec 2013, by Stephanie Hawthorne
Oncology Conference Insight: SABCS 2013 --- Endocrine therapy is a mainstay of therapy for breast cancer patients with estrogen receptor (ER) and/or progesterone receptor (PR) positive disease, with use in the adjuvant setting for early stage disease as well as in the metastatic setting. In the first-line metastatic setting, aromatase inhibitors (AI) can offer clinical benefit in post-menopausal ER+/PR+ patients, with progression-free survival (PFS) in clinical trials ranging from eight to 10 months.
Sequestration: A Practice Catastrophe or a Reduction in Profits?
15 May 2013, by Gordon Gochenauer
There has been a fair amount of talk lately about the impact of payment reductions for cancer care services by 2%, and a reduction in reimbursement for buy and bill cancer drugs from ASP + 6% to ASP +4.3. So what is the impact of sequestration on oncology – is it a practice catastrophe, or just a reduction in profits?
Reality or hype? The Egyptian healthcare ‘revolution’ post Arab Spring
17 Oct 2012, by Sherif Shafick
Since the 1960s, Egypt's health profile has grown to be more like developed countries, with longer life expectancy and higher productivity. Yet despite health programs to tackle Poliomyelitis, tuberculosis, viral hepatitis B/C and bilharziasis being offered at no cost to patients, disease rates for cancer, diabetes, heart and chronic respiratory are still high.
Building awareness of the psychological effects of psoriasis
5 Mar 2013, by Michael Fronstin
Have you ever felt embarrassed or ashamed to leave your house? Ever hesitate to wear short sleeves or shorts in the summer because you wanted to avoid someone else seeing your skin? Ever change the way you live your life because of a health-related issue? If you’re one of the 8 million Americans diagnosed with psoriasis then you probably know what I mean.